MX-1026: A phase 2 trial of nemabrutinib (MK-1026) in people with certain types of relapsed or refractory non-Hodgkin lymphoma

This trial is testing the medication nemtabrutinib in people with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL) or Waldenström macroglobulinaemia (WM) which has come back after (relapsed), or not responded (refractory) to treatment.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04728893

Trial aim and background  

The aim of this trial is to find out how safe and effective the medication nemabrutinib is in relapsed or refractory Cll, SLL, MZL, MCL, FL or WM. 

Nemabrutinib is a type of targeted treatment called a BTK inhibitor. It blocks to a protein called Bruton’s tyrosine kinase. This stops the B cells from growing out of control. Nemabrutinib is different from other BTK inhibitors in that it can also bind to some other proteins, and can bind to some common mutations. These mutations often make other BTK inhibitors ineffective long term.

Who can enter 

People with the following types of lymphoma may be eligible for this trial:

  • CLL or SLL which is refractory to, or has relapsed after two prior treatments for the first part of the study, and one for the second
  • MCL which is refractory to, or has relapsed after chemoimmunotherapy and a BTK inhibitor
  • MZL which is refractory to, or has relapsed after chemoimmunotherapy and a BTK inhibitor
  • FL which is refractory to, or has relapsed after chemoimmunotherapy
  • WM which is refractory to, or has relapsed after chemoimmunotherapy and a BTK-inhibitor

Locations 

Recruitment is taking place in the following UK locations:

  • The Christie NHS Foundation Trust, Manchester
  • British Haematology and Immunology Centre, Bristol
  • Nottingham University Hospitals NHS Trust, Nottingham
  • GenesisCare, Windsor
  • Sarah Cannon Research Institute, London
  • GenesisCare, Oxford
  • GenesisCare, Cambridge
  • The Royal Marsden NHS Foundation Trust, Surrey

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT04728893

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.